Around 13,000 people suffer from dust mite allergies and live with the symptoms everyday, however this is about to change.
The National Institute for Healthcare and Care Excellence (NICE) are recommending a tablet to help reduce symptoms.
Symptoms can include coughing, breathlessness, a runny nose and itchy skin.
But for those with a severe allergy it can debilitating and include fatigue, face swelling and have a high impact on sleep.
This cannot always be treated with typical nasal sprays and antihistamines.
Acarizax is the first sublingual allergy immunotherapy product to be assessed and recommended by NICE and will be the first of its kind to be available through the NHS.
It works by increasing your tolerance to dust mites which then reduces the severity of your symptoms and improves quality of life.
Before taking Acarizax doctors will conduct blood tests and skin prick tests to ensure no harm to the individuals taking the drug.
The first dose will then be given in hospital, to check if the person can tolerate it.
Acarizax is aimed to be taken everyday for 3 years to ensure the best outcomes and suitable for ages 12-65.
The treatment will be available in England within 3 months following NICE final guidance being published
LATEST: Washington DC plane crash disaster